Ignite Creation Date:
2024-05-06 @ 3:01 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04493138
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2020-07-27
Brief Title:
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or MyelodysplasticMyeloproliferative Neoplasm With FLT3 or CBL Mutations
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-21
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2020-07-27
First Submit QC Date:
July 27 2020
Study First Post Date:
2020-07-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-08
Last Update Post Date:
2024-07-03
Last Update Post Date Type:
ACTUAL